The diagnosis of acromegaly remains a significant clinical challenge, often delayed by six to ten years after symptom onset. This rare condition results from chronic growth hormone (GH) and insulin-like growth factor-I (IGF-I) excess. While dramatic facial changes are classic signs, many patients present with non-specific symptoms like sleep apnea, carpal tunnel syndrome, and arthralgia. Consequently, clinicians must maintain a high index of suspicion to ensure earlier intervention and better patient outcomes.

Biochemical Approaches to the Diagnosis of Acromegaly

Serum IGF-I is the most reliable initial screening test for suspected cases. This hormone remains stable throughout the day and accurately reflects integrated GH levels. However, physicians must interpret results carefully. Factors such as age, sex, and comorbidities like diabetes, renal disease, or obesity can influence IGF-I values. Furthermore, newer LC-MS/MS assays offer better specificity compared to traditional ligand-binding assays, helping to harmonize results across different laboratories.

If IGF-I results are borderline or discordant with the clinical picture, clinicians should perform an oral glucose tolerance test (OGTT). The OGTT serves as the gold-standard confirmatory test. In healthy individuals, glucose load suppresses GH levels. Conversely, failure to suppress GH below a nadir of ∼0.4 µg/L suggests a somatotroph adenoma. This threshold has lowered in recent years due to the adoption of ultrasensitive GH assays.

Technological Innovations in Diagnosis

Artificial intelligence (AI) is revolutionizing how we approach the diagnosis of acromegaly. Recent studies highlight the efficacy of AI-driven facial recognition and hand image analysis. These tools can identify subtle morphological changes long before they become clinically obvious to the human eye. Additionally, advanced imaging like high-resolution PET/MRI and radiomics provide detailed insights into pituitary adenomas, facilitating more precise surgical planning and long-term management.

Frequently Asked Questions

Why is IGF-I preferred over GH for initial screening?

IGF-I levels are stable and do not fluctuate like GH, which is secreted in pulses. Therefore, a single IGF-I measurement provides a more accurate reflection of chronic growth hormone excess than a random GH sample.

What is the role of OGTT in acromegaly?

The oral glucose tolerance test (OGTT) is the gold standard for confirmation. It measures GH suppression; a nadir GH above 0.4 µg/L typically confirms the diagnosis when interpreted alongside elevated IGF-I levels.

How does AI assist in early detection?

AI algorithms analyze facial geometry and hand images to detect morphological patterns associated with acromegaly. These systems often outperform human experts in spotting early, subtle changes, potentially reducing the decade-long diagnostic delay.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace consultation with a qualified healthcare professional. Refer to the latest local and national guidelines for clinical practice.

References

Yogi-Morren D et al. Diagnosis of Acromegaly. J Clin Endocrinol Metab. 2026 Apr 29. doi: undefined. PMID: 42056759.

Giustina A et al. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024 Feb;27(1):7-22.

Ohmachi Y et al. AI Model Can Diagnose Acromegaly Using Dorsal Hand, Fist Images. J Clin Endocrinol Metab. 2026 Feb 27.